US LNG Headed to Asia Fetches More Than Cargoes to Europe for First Time in 7 Months
Liquefied natural gas traders can make a better profit from selling US LNG cargoes in Asia than offering the fuel in Europe, an opportunity that opened up for the first time in seven months, according to data from analytics firm Spark Commodities.
The US-to-Asia arbitrage window emerged following a series of production outages in Asia that have shrunk short-term supplies in the Pacific Basin, including in Malaysia, Brunei and Australia. Meanwhile, European gas prices have eased on storage refills and subdued demand.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Women are getting wealthier — and they don't invest the same way as men
Women are becoming richer, and they're changing the face of wealth. According to a report by McKinsey published last month, women control about a third of all retail financial assets in the US and the European Union. By 2030, that proportion is expected to rise to between 40% to 45%, wrote Cristina Catania, global co-convener and European lead for the risk and resilience practice, and Jill Zucker, senior partner and co-leader of McKinsey's global growth transformation service line. The report is based on a survey of about 13,000 American and European investors, nearly half of whom were female financial decision makers. It found that between 2018 and 2023, global wealth rose by 43%, but jumped by 51% for women. Women's expanding control of assets is being driven by a combination of factors, including a continuing decline in marriage rates, the ongoing boost in women's average earnings, demographic trends like longer life expectancies, and a broad shift in attitudes about women managing their own finances. Risk doesn't equal reward As women become wealthier through investing, it's becoming clearer that they don't approach it the same way as men. "Women are much more risk-aware," Anna-Sophie Hartvigsen, cofounder of financial education and investment platform Female Invest, told Business Insider. "I would like to call it much more realistic in their own ability to invest." She said women are less likely than men to invest emotionally. "On average, men trade a lot more often than women because they believe they can beat the market or they read something in the news, and they get pumped up or afraid, and then they invest based on that," Hartvigsen said. Female investors, in her view, tend to be more calm, more realistic, and better at assessing risk. However, Katie Geery, an advisor at Rise Private Wealth Management, says being more cautious can also hold women back by leading them to miss out on opportunities to build wealth. "It is important to work with a trusted financial advisor who understands your risk tolerance and can walk you through making well-educated investment decisions based on your long-term goals," she told BI. Returns aren't everything The aims of investing also sometimes differ between men and women. "Women prefer to invest toward achieving specific goals rather than chasing the highest returns," said Avanti Shetye, financial planner at Wealthwyzr. Geery said female investors tend to be more focused on philanthropy and gifting. They often consider their values when buying stock and want their purchases to help make a better impact on the world. "Women often seek financial advisors who are empathetic and take the time to get to know them on a more personal level to gain a deeper understanding of their goals and values," she said. On Female Invest, Hartvigsen said the principles its members care about the most include climate, especially a firm's carbon footprint, and diversity in leadership, in terms of a board having a good gender balance. Start investing early For Shetye, it's important to start investing early. "Women tend to be primary caregivers for children or aging parents and often take unpaid time off," she said. "Not only that, women statistically live longer than men, which implies that women would need to invest as much as they can as early as possible so that their portfolios last them through retirement." Hartvigsen said long-term financial planning is vital: "When you do that, it doesn't matter what happens today." Both agree that this plan should be grounded in expert advice. "Working with a financial planner whose planning process is rooted in financial education can help provide comfort and security to stay consistent even in the roughest of markets," Shetye said. But she also believes that practice is more important than perfection. "You are never going to know everything there is to know about investing," Shetye said. "The key is consistency, and time will do the heavy lifting." Hartvigsen advises her clients to invest monthly on the same day and to diversify their investments. "If you do that, historically, it has been near impossible not to make money in the long run."
The Hill
an hour ago
- The Hill
Food and Drug Administration staff cuts may hinder US biomedical innovation
President Trump has rightly emphasized restoring America's economic and strategic independence — from reshoring pharmaceutical production to cutting regulatory red tape. But not all reforms are created equal. Recent restructuring efforts at the Food and Drug Administration may have been well-intentioned, but they risk undermining the very innovation and domestic capacity the president seeks to promote. In March, Health and Human Services Secretary Robert F. Kennedy Jr. announced a sweeping reorganization of the agency, which in part included the elimination of 3,500 full-time employees at the Food and Drug Administration — many of them senior scientific staff and experienced regulators who served as institutional pillars across drug review divisions. While we all support government efficiency and the secretary's efforts to create a gold-standard regulatory agency, the loss of this institutional memory risks hobbling the expedited pathways that small biotech firms rely on to deliver therapies for rare and life-threatening diseases. Unfortunately, the impact of these cuts is not theoretical. The Wall Street Journal has reported that some biotech firms have had to delay or cancel clinical trials due to lack of timely Food and Drug Administration guidance. One California biotech firm facing unpredictable delays has even turned to European regulators to move forward with a clinical trial — effectively offshoring American capital, investment and jobs. Others have reported receiving conflicting and confusing feedback from inexperienced FDA staff or no response at all on time-sensitive requests. But such issues don't just affect companies; they hurt patients, too. Innovation in gene therapies, cancer immunotherapies, and treatments for rare diseases depend on regulatory clarity and speed. Without senior staff to help clarify agency positions, decisions are either delayed or driven by less-experienced personnel unfamiliar with long-standing scientific standards. It's no surprise then that over 200 biotech CEOs, patient advocates and investors — many of them strong supporters of FDA modernization — have expressed their concerns in a letter to Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy (R-La.). As a former member of Congress who sat on the Appropriations subcommittee overseeing the FDA, I have long supported targeted reforms to make the agency more nimble and responsive. But there is a fine line between streamlining operations and cutting the institutional capacity necessary to do the job. Removing experienced drug reviewers before an adequate backup plan can be put into place not only jeopardizes U.S. safety standards but also undermines our competitive edge. This matter is not merely a domestic problem; it's a global race. Since 2014, the number of biomedical drugs under development in China has grown twelvefold. Meanwhile, innovation in the U.S. has remained relatively flat. If trends continue, China could match or surpass the U.S. in biomedical innovation within the decade. We have seen this movie before — in semiconductors, in telecommunications, in clean energy. We cannot afford to let biotech go the same way. The Trump administration's tariff policy was designed to bring pharmaceutical manufacturing back to U.S. shores. But how can we expect capital to stay in the U.S. if our regulatory infrastructure cannot deliver? Delays and unpredictability at the FDA don't just slow down science — they push investors to look elsewhere. Even the user fee system — critical to funding timely drug reviews and a source of government revenue — has been impacted by the reduction in force. Staff who oversaw the reauthorization of the Prescription Drug User Fee Act have been laid off, raising questions about whether the agency will even be able to continue to collect user fees and whether these government cuts will actually end up costing taxpayers in the long run. Of course, Kennedy has long been a vocal advocate for health reform. His Make America Healthy Again agenda's focus on combatting chronic diseases and enhancing nutritional standards deserves attention. His focus for such reform is where his background and passion can lead to meaningful improvements. But when it comes to regulating complex biologics and therapeutics, we must be careful about taking actions that could inadvertently stymie scientific progress. President Trump's vision for American self-reliance will only succeed if it's built on a foundation of regulatory competence and stability. Swift actions should therefore be taken to restore the FDA's core functions, rehire critical staff and unfreeze the hiring of roles essential to America's leadership in biomedical science. The stakes — for patients, for innovation and for national security — are simply too high to ignore. John T. Doolittle is a former member of Congress who served on the Agriculture, Rural Development, FDA, and Related Agencies subcommittee of the Committee on Appropriations.
Yahoo
an hour ago
- Yahoo
Cyberway Product Innovation Platform: Empowering Enterprise Innovation Processes and Building Exceptional Product Strength
GUANGZHOU , June 22, 2025 /PRNewswire/ -- In the fiercely competitive FMCG market, only efficient innovation can create a true competitive edge. As consumer preferences change rapidly and the market environment remains uncertain, how can companies precisely identify needs, execute efficiently, and continuously optimize their strategies? The Cyberway Product Innovation Platform empowers FMCG enterprises to achieve sustainable growth by providing powerful capabilities in pre-planning insight, in-process control, and post-launch analytics—ultimately enabling the development of exceptional product strength. Before: AI-Powered Foresight for Accurate Market Opportunity Detection AI Opportunity Discovery: Real-time industry data, user behavior, and competitor insights are captured to automatically identify blue ocean markets and unmet needs—fueling inspiration for new product planning. Accelerate Opportunity Capture: Shorten market research cycles and improve speed and accuracy of opportunity identification. AI-Driven Product Definition: Using opportunity and competitor analysis, combined with internal product knowledge bases, the system intelligently generates product concepts, optimizes configurations, and refines packaging and formulas. Agile Response: Ensure product design closely aligns with market needs and competition, allowing rapid focus on core value and improving product-market fit. End-to-End User Demand Management: A comprehensive demand management framework tracks records, statuses, and feedback, aggregating omnichannel voice of customer with AI to identify high-value & Accurate: By realizing and verifying demand in closed-loop cycles, continuously refine product performance, minimize resource waste, and pave the way for the next breakout product. During: Efficient Execution to Deliver Outstanding Products Scientific Project Management System: Integrates visual dashboards, all-in-one workbenches, and real-time notifications via Feishu, WeCom, and DingTalk for full project transparency and synchronized decision-making across teams. Core Value: Reduce communication overhead, improve collaboration efficiency, and prevent project delays. Standardized Project Workflow: Based on industry templates and task libraries, enabling tiered and structured project management tailored to channel requirements. Flexible Control: Guarantees high-quality delivery while allowing adaptive workflows, ensuring key tasks succeed the first time. Cross-Functional Online Collaboration: Integrates marketing, go-to-market, and product workflows to shorten timelines. Interlocked nodes require mutual confirmation to ensure stability and avoid cost waste. Key Feature: Enables synergistic cooperation across departments for performance greater than the sum of its parts. AI Marketing: Tracks competitor strategies and social trends in real time, dynamically generating targeted content and pricing strategies using internal knowledge. Efficient & Agile: Accelerates creative production and drives an integrated "strategy-content-pricing" engine for rapid market response. Online Knowledge Repository: A dedicated enterprise R&D knowledge base aggregating key data such as risk warnings, solutions, and technical documentation. Significant Boost: Empowers faster troubleshooting and prevents redundant errors in R&D. Comprehensive Quality Control System: Embeds IPD checkpoints and technical reviews to govern key milestones; incorporates risk management for prevention, monitoring, and post-analysis. Ultimate Goal: Ensure high-quality project delivery while minimizing potential risks. After: Data-Driven Innovation Strategy Optimization Project Review: Compare project baselines with actual execution to deeply analyze quality, timeline, and cost performance. Deeper Insights: Identify key factors that influence project success. Go-to-Market Tracking: Monitor GMV trends across e-commerce platforms, VOC on social media, and promotional campaign outcomes to pinpoint growth opportunities and risks, driving agile strategy iteration. Advanced Capabilities: Fuel product iteration and innovation, providing a core foundation for the next-generation breakout product. Data Asset Management: Leverages delivery data and gate review points to auto-update master product data, creating a unified view with field supplementation and relationship validation. Long-Term Value: Enables full-lifecycle product data management, enhancing both data quality and business utility. The Cyberway Product Innovation Collaboration Platform is a powerful enabler for FMCG enterprises to enhance product innovation with AI, reduce waste, shorten R&D cycles, and create market bestsellers. From ideation to launch and ongoing optimization, the platform empowers excellence at every stage—allowing businesses to stand out in an intensely competitive landscape. We look forward to partnering with more brands to explore new ways of innovation and co-create the next market blockbuster! Website: Email：Marketing@ View original content: SOURCE Cyberway Information Technology Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
